Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort study

Journal

BMC Cancer

Journal Volume

16

Journal Issue

1

Date Issued

2016

Author(s)

Chen H.-M.

Lin Y.-L.

Lai M.-S.

DOI

10.1186/s12885-016-2358-2

URI

https://www.scopus.com/inward/record.uri?eid=2-s2.0-84970016836&doi=10.1186%2fs12885-016-2358-2&partnerID=40&md5=91d3bc0282e8a9a4eda6fb6f6b7d4382

https://scholars.lib.ntu.edu.tw/handle/123456789/612563

SDGs

[SDGs]SDG3

Publisher

BioMed Central Ltd.

Type

journal article